IRulya Therapeutics Inc. (IRLA) Executive Compensation
IRulya Therapeutics Inc. (IRLA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: IRLA
CIK: 1662774
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
BDO USA, P.C.
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerDaniel Harris
Audit LocationSan Jose, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G | 2026-10-14 | — | SCHEDULE 13G Filing | 0001104659-26-115859 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-10-14 | — | SCHEDULE 13G Filing | 0001193125-26-421651 | View SEC Doc Filr Page |
| 8-K | 2026-10-09 | 2026-10-07 | 8-K | 0001193125-26-418538 | View SEC Doc Filr Page |
| S-8 | 2026-10-08 | — | S-8 | 0001193125-26-418091 | View SEC Doc Filr Page |
| 8-K | 2026-10-06 | 2026-10-06 | 8-K | 0001193125-26-415730 | View SEC Doc Filr Page |
| DEFA14A | 2026-10-02 | — | DEFA14A | 0001193125-26-411262 | View SEC Doc Filr Page |
| 8-K | 2026-10-02 | 2026-09-30 | 8-K | 0001193125-26-411260 | View SEC Doc Filr Page |
| 8-K | 2026-09-14 | 2026-09-08 | 8-K | 0001193125-26-390652 | View SEC Doc Filr Page |
| 8-K | 2026-09-04 | 2026-08-31 | 8-K | 0001193125-26-382838 | View SEC Doc Filr Page |
| 8-K | 2026-08-27 | 2026-08-23 | 8-K | 0001193125-26-371389 | View SEC Doc Filr Page |
| DEF 14A | 2026-08-25 | 2026-10-06 | DEF 14A | 0001193125-26-364220 | View SEC Doc Filr Page |
| EFFECT | 2026-08-24 | — | EFFECT Filing | 9999999995-26-002741 | View SEC Doc Filr Page |
| 8-K | 2026-08-17 | 2026-08-17 | 8-K | 0001193125-26-353141 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-14 | — | SCHEDULE 13G Filing | 0001193125-26-352966 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001104659-26-097291 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | 10-Q | 0001193125-26-352201 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-14 | — | SCHEDULE 13G Filing | 0001172661-26-003692 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-14 | 8-K | 0001193125-26-350568 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-14 | — | SCHEDULE 13G Filing | 0001172661-26-003433 | View SEC Doc Filr Page |
| S-3/A | 2026-08-05 | — | S-3/A | 0001193125-26-333764 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-04 | — | SCHEDULE 13G Filing | 0002050709-26-000021 | View SEC Doc Filr Page |
| 8-K | 2026-07-31 | 2026-07-29 | 8-K | 0001193125-26-328784 | View SEC Doc Filr Page |
| PRE 14A | 2026-07-31 | 2026-07-31 | PRE 14A | 0001193125-26-328777 | View SEC Doc Filr Page |
| S-3 | 2026-07-31 | — | S-3 | 0001193125-26-328769 | View SEC Doc Filr Page |
| 8-K/A | 2026-07-30 | 2026-05-17 | 8-K/A | 0001193125-26-324786 | View SEC Doc Filr Page |